Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

2020267 citationsJournal Articlebronze Open Access

Authors

Vupanorsen results in a favourable lipid/lipoprotein profile and provides a potential strategy for residual cardiovascular risk reduction.

Good health and well-being

Published in: European Heart Journal

Volume 41, Issue 40, pp. 3936-3945

Field-Weighted Citation Impact: 26.53